WO2006032759A1 - Utilisation du metronidazole en combinaison avec de l'acide azelaique pour le traitement de la rosacee - Google Patents
Utilisation du metronidazole en combinaison avec de l'acide azelaique pour le traitement de la rosacee Download PDFInfo
- Publication number
- WO2006032759A1 WO2006032759A1 PCT/FR2005/002281 FR2005002281W WO2006032759A1 WO 2006032759 A1 WO2006032759 A1 WO 2006032759A1 FR 2005002281 W FR2005002281 W FR 2005002281W WO 2006032759 A1 WO2006032759 A1 WO 2006032759A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- metronidazole
- azelaic acid
- rosacea
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
Definitions
- the present invention relates to a pharmaceutical composition for the treatment of rosacea and, more particularly, to the inflammatory component of this condition. It further relates to the use of such a composition for the manufacture of a medicament for the treatment of rosacea.
- Rosacea is a chronic and progressive joint inflammatory dermatosis related to vascular relaxation. It mainly affects the party
- Rosacea usually occurs between the ages of 25 and 70, and is much more common in fair-skinned people. It affects women in particular, although this condition is usually
- Rosacea is chronic and persists for years with periods of exacerbation and remission.
- rosacea The pathogenesis of rosacea is poorly understood. Many factors can be involved without necessarily inducing this condition. These are for example psychological factors, gastrointestinal disorders, environmental factors (exposure to the sun, temperature, humidity), emotional (stress), food (alcohol, spices), hormonal, vascular, or infection with Helicobacter pillori.
- Rosacea evolves in 4 stages, but passage through all stages is not obligatory:
- stage 2 erythemato-telangiectatic (around 30 years).
- the malar areas are diffusely red.
- stage 1 the redness is permanent.
- the cheeks the chin and the middle part of the forehead can be affected.
- s ⁇ tade ⁇ 3 papulo-pustules (around 40 years).
- On a "background of erythema develop papules and pustules a few millimeters in diameter, without associated comedones.
- This skin disease can be extensive, sometimes to the bald part of the scalp in men, but from the area around the Patients complain of sensitive skin, with subjective intolerance to most topical and oily cosmetics.
- stage 4 of rhinophyma (around 50 years or later). This late phase mainly affects men, unlike other stages.
- the nose is enlarged, diffusely red and the follicular orifices are dilated.
- the skin gradually thickens.
- rosacea can be treated with active agents such as antiseborrhoeic agents and anti-infectives, for example benzoyl peroxide or retinoic acid.
- active agents such as antiseborrhoeic agents and anti-infectives, for example benzoyl peroxide or retinoic acid.
- active agents such as antiseborrhoeic agents and anti-infectives, for example benzoyl peroxide or retinoic acid.
- active agents such as antiseborrhoeic agents and anti-infectives, for example benzoyl peroxide or retinoic acid.
- benzoyl peroxide or retinoic acid for example benzoyl peroxide or retinoic acid.
- these treatments have unpleasant side effects for the patient, such as irritation or intolerance phenomena.
- therapies against this condition we are still looking for an effective treatment and without risk for the patient.
- the pharmaceutical compositions according to the invention comprise at least two active ingredients: metroni
- Metronidazole or (2-methyl-5-nitroimidazolyl) ethanol, is known in the prior art for its antibacterial, antiparasitic and antiprotozoal properties. It has a selective toxicity towards anaerobic microorganisms as well as hypoxic cells. ⁇ ⁇ u. level of these """derhTées, metronidazole is reduced to derivatives capable of altering DNA structure of these cells.
- the Applicant has recently demonstrated the interesting properties of metronidazole on cutaneous inflammation and, more particularly, on the inflammatory component in rosacea.
- Azelaic acid or 1,7-heptanedicarboxylic acid, is known in the prior art for its antibacterial and comedolytic properties.
- azelaic acid has a different bacteriolytic activity than metronidazole.
- the patent application WO2003 / 061766 suggested topical compositions containing active ingredients used alone or in combination with a mixture of ethyllinoleic and triethylcitric acids.
- Metronidazole and azelaic acid are cited among a list of active agents that can be used in said pharmaceutical composition. However, no embodiment discloses a composition comprising
- a problem to be solved by the invention is to provide a pharmaceutical composition comprising metronidazole and azelaic acid, which shows improved efficacy in the treatment of rosacea as well as the use of a such a composition for the preparation of a medicament.
- the solution of the invention to this problem arises from the fact that the Applicant has discovered that, surprisingly, the combination of metronidazole with azelaic acid, in suitable concentrations, makes it possible to obtain a synergistic effect in the treatment. skin inflammation and, in particular, the inflammatory component in rosacea.
- the present invention relates to a pharmaceutical composition for the treatment of rosacea comprising, in a pharmaceutically acceptable medium, at least metronidazole or a pharmaceutically acceptable derivative thereof and azelaic acid or one of its derivatives pharmaceutically acceptable, at concentrations such that a synergistic effect between metronidazole and azelaic acid is observable.
- concentration of metronidazole is equal to 0.75% by weight of the total weight of the composition
- the concentration of azelaic acid is less than 10% by weight of the total weight of the composition.
- the invention relates to the use of a composition for the manufacture of a medicament for the treatment of rosacea.
- Metronidazole and azelaic acid are present in the composition according to the invention in concentrations such that they act in synergy to confer on the composition a therapeutic effect greater than the theoretical effect obtained by adding together the effects obtained by each of the two assets taken separately.
- metronidazole is used at concentrations between 0.001 and 20% by weight relative to the total weight of the composition and, more preferably, between 0.1 and 2%, in particular 0.75%, 1%, 1.5% or 2%.
- the concentration of azelaic acid used is less than 10% by weight of the total weight of the composition. It is preferably between 0.5 and 8% by weight of this total weight and, more preferably, between 1 and 7% by weight%, in particular 2%, 3%, 6% or 7%.
- azelaic acid less than 10% by weight, combined in the same composition with 0.75% by weight of metronidazole, have an efficiency close to one combination of azelaic acid, at a concentration equal to 20% by weight, with 0.75% by weight of metronidazole.
- composition which is the subject of the present invention is a dermatological composition, for topical administration to the skin.
- composition which contains a combination of metronidazole and azelaic acid at concentrations such that a synergistic effect between metronidazole and azelaic acid is substantially more effective than a composition comprising metronidazole alone or azelaic acid alone,
- the use of a combination of azelaic acid and metronidazole makes it possible to shorten the treatment period, the composition which contains a mixture of metronidazole and azelaic acid for topical application, makes it possible to use a lower dose of azelaic acid or even metronidazole, and thus to reduce the side effects related, on the one hand, to metronidazole and on the other hand, azelaic acid.
- the present invention also relates to a pharmaceutical composition as defined above, characterized in that it shows a synergistic effect between metronidazole and azelaic acid in the treatment of disorders of the cutaneous vasculature caused by rosacea.
- Treatment of the disorders of the cutaneous vascularization means according to the present invention, the treatment and / or the prevention of such disorder.
- treatment of rosacea is meant according to the present invention, the treatment and / or prevention of rosacea, at one or more of the stages described above.
- the use of the composition is intended for the treatment of the first stage of rosacea.
- the use of the composition is intended for the treatment of the second stage of rosacea.
- the use of the composition is intended for the treatment of the third stage of rosacea.
- the use of the composition is intended for the treatment of the fourth stage of rosacea.
- the composition contains 0.001 to 20% by weight of metronidazole and 0.5 to 8% by weight of azelaic acid, preferably from 0.1 to 2% by weight of metronidazole and 1 to 7% by weight of azelaic acid expressed as percentage by weight relative to the total weight of the ⁇ " ⁇ ⁇ ccJmp3s ⁇ îon in particular, the composition contains 0.75%, 1%, 1.5% or 2% by weight of metronidazole and 2%, 3%, 6% or 7% by weight of azelaic acid expressed as a percentage by weight relative to the total weight of the composition, and the present invention relates, in addition to the use of metronidazole and the acid azelaic, the use of derivatives thereof.
- Derivatives are compounds which are distinguished from metronidazole and azelaic acid, by substitution, addition or deletion of one or more chemical groups and having substantially the same activity as well. that their salts with an acid or a phar base Mac
- compositions of the invention comprise, in addition to metronidazole and azelaic acid, at least one other therapeutic agent capable of increasing the effectiveness of the treatment.
- agents include antibiotics, antibacterials, antivirals, antiparasitics, antifungals, anesthetics, analgesics, antiallergics, retinoids, anti-free radicals, antiprurigines, keratolytics, antiseborrhoeic agents, antihistamines, sulfides, immunosuppressive or antiproliferative products or a mixture thereof.
- the compositions of the invention may further comprise any additive usually used in the pharmaceutical, dermatological, compatible with metronidazole and azelaic acid.
- these optional additional compounds, and / or their amount such that the advantageous properties of the composition according to the invention are not, or not substantially impaired.
- additives can be present in the composition in a proportion of 0 to 20% by weight relative to the total weight of the composition.
- sequestering agents examples include ethylenediamine tetracetic acid (EDTA), as well as its derivatives or salts, dihydroxyethylglycine, citric acid, tartaric acid, or mixtures thereof.
- EDTA ethylenediamine tetracetic acid
- preservatives examples include benzalkonium chloride, phenoxyethanol, benzyl alcohol, diazolidinyl urea, parabens, or mixtures thereof.
- humectants examples include glycerin and sorbitol.
- compositions of the invention are capable of containing one or more propenetrating agents in preferential concentrations ranging from 0 to 20% and more preferably ranging from 0.6 to 3% by weight relative to the total weight of the composition.
- propenetrating agents it is preferable to use, without this list being limiting, compounds such as propylene glycol, dipropylene glycol, propylene glycol dipelargonate, lauroglycol and ethoxydiglycol.
- compositions according to the invention are advantageousously, the compositions according to the invention.
- compositions of the present invention may be in any of the galenical forms normally used for topical application, especially in the form of aqueous, hydroalcoholic or oily solutions, lotion-type dispersions, aqueous, anhydrous or lipophilic gels, liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O / W) or conversely (W / O), or suspensions or emulsions of soft, semi-liquid or solid consistency cream type, gel or ointment or micro-emulsions, microcapsules, microparticles or vesicular dispersions of ionic and / or nonionic type.
- the creams can be formulated from a mixture of mineral oil, or a mixture of beeswax and water which emulsifies instantly, in which metronidazole is added, dissolved in a small amount of oil such as almond oil.
- the creams can be formulated from a mixture of mineral oil, or a mixture of beeswax and water which emulsifies instantly, in which metronidazole and the acid are added.
- azelaic dissolved in a small amount of oil such as almond oil.
- the lotions can be prepared by dissolving metronidazole and azelaic acid in a high molecular weight alcohol, such as polyethylene glycol.
- a high molecular weight alcohol such as polyethylene glycol.
- the ointments can be formulated by mixing a solution of metronidazole and azelaic acid in a hui-the-fee ⁇ e-that-t'î ⁇ u ⁇ ⁇ ⁇ e ⁇ d ⁇ 'amand ⁇ T ⁇ in heated paraffin, and then letting cool The mixture.
- the gels can be prepared preferably by dispersing or dissolving metronidazole and azelaic acid in a suitable ratio in a carbomer, poloxamer or cellulosic type gel.
- compositions according to the invention mention may be made of those comprising an active phase containing (expressed as a percentage by weight):
- metronidazole 0.001 to 20%, preferably 0.1 to 2%, of metronidazole;
- azelaic acid 0.5 to 8%, preferably 1 to 7% of azelaic acid; and an aqueous phase comprising a gelling agent and water.
- the aqueous phase of a composition according to the invention in the form of an emulsion may comprise water, a floral water such as cornflower water, or a natural thermal or mineral water, for example chosen from the water of Vittel, the waters of the Vichy basin, the water of Uriage, the water of the Roche Posay, the water of the Bourboule, the water of Enghien-les-Bains, the water of Saint Gervais-les-Bains, the water of Néris-les-Bains, the water Allevard-les-Bains, the water of Digne, the water of Maizines, the water of Neyrac-les-Bains, the water of Lons-le-Saunier, the Eaux Bonnes, the water of Rochefort, the water of Saint Christau, the water of the Fumades and the water of Tercis-les-bains f the water of Avène or the water of Aix les Bains.
- a floral water such as cornflower water
- a natural thermal or mineral water for example chosen from the
- Said aqueous phase may be present in a content of between 10 and 90% by weight relative to the total weight of the composition, preferably in the range 20% by weight, by way of non-limiting examples, mention may be made of gelling agents of the polyacrylamide family, such as the Sodium acryloyldimethyltaurate copolymer / isohexadecane / polysorbate 80 mixture sold under the name Simulgel TM 600 by the company Seppic TM, the polyacrylamide / isoparaffin C13-14 / laureth-7 mixture, for example that sold under the name Sepigel 305 TM by the company Seppic TM, the family of acrylic polymers coupled to hydrophobic chains such as the PEG-150 / decyl / SMDI copolymer sold under the name Aculyn 44 TM (polycondensate comprising at least as elements a polyethylene glycol containing 150 or 180 moles of ethylene oxide, decyl alcohol and methylene bis (4-cyclohexyl
- the preferred gelling agents are derived from the family of polyacrylamides such as Simulgel 600 TM or Sepigel 305 TM or mixtures thereof.
- the gelling agent as described above may be used at preferential concentrations ranging from 0.1 to 15% and, more preferably, from 0.5 to 5%.
- Gels can be prepared preferably by dispersing or dissolving metronidazole in a appropriate ratio in a carbomer, poloxamer or cellulosic type gel.
- Carbopol 980 (GOODRICH) 0, 6 g
- Polyethylene glycol 400 2 g Methyl glucose sesquistearate 5g polyoxyethylenated to 20 moles EO
- Carbomer 940 0.1 g Water ⁇ __ -qsp 100 -g-
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05802503A EP1791598A1 (fr) | 2004-09-17 | 2005-09-14 | Utilisation du metronidazole en combinaison avec de l'acide azelaique pour le traitement de la rosacee |
JP2007531796A JP2008513420A (ja) | 2004-09-17 | 2005-09-14 | アゼライン酸と組合せたメトロニダゾールのしゅさの処置のための使用 |
CA002578121A CA2578121A1 (fr) | 2004-09-17 | 2005-09-14 | Utilisation du metronidazole en combinaison avec de l'acide azelaique pour le traitement de la rosacee |
US11/723,378 US20070219263A1 (en) | 2004-09-17 | 2007-03-19 | Metronidazole/azelaic acid compositions for the treatment of rosacea |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0409879 | 2004-09-17 | ||
FR0409879A FR2875404B1 (fr) | 2004-09-17 | 2004-09-17 | Composition pharmaceutique pour le traitement de la rosacee |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/723,378 Continuation US20070219263A1 (en) | 2004-09-17 | 2007-03-19 | Metronidazole/azelaic acid compositions for the treatment of rosacea |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006032759A1 true WO2006032759A1 (fr) | 2006-03-30 |
Family
ID=34951421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2005/002281 WO2006032759A1 (fr) | 2004-09-17 | 2005-09-14 | Utilisation du metronidazole en combinaison avec de l'acide azelaique pour le traitement de la rosacee |
Country Status (6)
Country | Link |
---|---|
US (1) | US20070219263A1 (fr) |
EP (1) | EP1791598A1 (fr) |
JP (1) | JP2008513420A (fr) |
CA (1) | CA2578121A1 (fr) |
FR (1) | FR2875404B1 (fr) |
WO (1) | WO2006032759A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2316308A1 (es) * | 2008-04-30 | 2009-04-01 | Fundacion Universitaria San Pablo - Ceu | Medicamente a base de metronidazol y acido azelaico para el tratamiento por via topica de la enfermedad rosacea de mejor asimilacion, y procedimiento de preparacion. |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4045030A4 (fr) * | 2019-10-16 | 2024-03-13 | Curology Inc | Compositions et méthodes de traitement de l'acné et du photovieillissement |
RU2741988C1 (ru) * | 2020-08-05 | 2021-02-01 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Амурская государственная медицинская академия" Министерства здравоохранения Российской Федерации | Способ коррекции антиоксидантного статуса при лечении больных эритематозно-телеангиэктатической и папуло-пустулезной формами розацеа легкой и средней степени тяжести |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1393221A (zh) * | 2001-06-22 | 2003-01-29 | 姜涛 | 一种治疗痤疮的药液 |
WO2004022046A1 (fr) * | 2002-09-05 | 2004-03-18 | Reza Babapour | Composition et procede de traitement de la peau |
WO2004108143A1 (fr) * | 2003-06-10 | 2004-12-16 | Schering Aktiengesellschaft | Composition a base d'acides alkyldicarboxyliques et d'un principe actif pharmaceutique |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050026982A1 (en) * | 2003-06-10 | 2005-02-03 | Soenke Johannsen | Composition that consists of alkanedicarboxylic acids and a pharmaceutical active ingredient |
-
2004
- 2004-09-17 FR FR0409879A patent/FR2875404B1/fr not_active Expired - Fee Related
-
2005
- 2005-09-14 JP JP2007531796A patent/JP2008513420A/ja not_active Withdrawn
- 2005-09-14 WO PCT/FR2005/002281 patent/WO2006032759A1/fr active Application Filing
- 2005-09-14 CA CA002578121A patent/CA2578121A1/fr not_active Abandoned
- 2005-09-14 EP EP05802503A patent/EP1791598A1/fr not_active Withdrawn
-
2007
- 2007-03-19 US US11/723,378 patent/US20070219263A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1393221A (zh) * | 2001-06-22 | 2003-01-29 | 姜涛 | 一种治疗痤疮的药液 |
WO2004022046A1 (fr) * | 2002-09-05 | 2004-03-18 | Reza Babapour | Composition et procede de traitement de la peau |
WO2004108143A1 (fr) * | 2003-06-10 | 2004-12-16 | Schering Aktiengesellschaft | Composition a base d'acides alkyldicarboxyliques et d'un principe actif pharmaceutique |
Non-Patent Citations (4)
Title |
---|
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2000, KURDINA M I: "Azelaic acid (skinoren) for rosacea therapy", XP002319036, Database accession no. PREV200000291051 * |
DATABASE WPI Section Ch Week 200343, Derwent World Patents Index; Class B03, AN 2003-450220, XP002319030 * |
DEL ROSSO J Q: "MEDICAL TREATMENT OF ROSACEA WITH EMPHASIS ON TOPICAL THERAPIES", EXPERT OPINION ON PHARMACOTHERAPY, ASHLEY, LONDON,, GB, vol. 5, no. 1, January 2004 (2004-01-01), pages 5 - 13, XP009034172, ISSN: 1465-6566 * |
VESTNIK DERMATOLOGII I VENEROLOGII, no. 1, 2000, pages 34 - 36, ISSN: 0042-4609 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2316308A1 (es) * | 2008-04-30 | 2009-04-01 | Fundacion Universitaria San Pablo - Ceu | Medicamente a base de metronidazol y acido azelaico para el tratamiento por via topica de la enfermedad rosacea de mejor asimilacion, y procedimiento de preparacion. |
Also Published As
Publication number | Publication date |
---|---|
FR2875404A1 (fr) | 2006-03-24 |
JP2008513420A (ja) | 2008-05-01 |
CA2578121A1 (fr) | 2006-03-30 |
FR2875404B1 (fr) | 2008-10-03 |
EP1791598A1 (fr) | 2007-06-06 |
US20070219263A1 (en) | 2007-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR2909000A1 (fr) | Compositions comprenant du peroxyde de benzoyle, au moins un derive de l'acide naphtoique et au moins un compose de type polymeres de polyurethane ou des derives de celui-ci, et leurs utilisations. | |
EP1898907A1 (fr) | Composition a base d une avermectine et de metronidazole notamment pour le traitement de la rosacee | |
EP1898933A1 (fr) | Composition a base d une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee | |
EP1861083B1 (fr) | Composition à base d'une avermectine et d'acide azélaïque notamment pour le traitement de la rosacée | |
WO2006032759A1 (fr) | Utilisation du metronidazole en combinaison avec de l'acide azelaique pour le traitement de la rosacee | |
WO2005089871A1 (fr) | Utilisation d’un compose antagoniste d’au moins un recepteur choisi dans le groupe comprenant les recepteurs beta-adrenergiques, le recepteur at1, 5-ht5 et de la galanine, pour la preparation d’une composition pharmaceutique destinee a traiter la rosacee | |
FR2862537A1 (fr) | Utilisation du fepradinol pour la preparation d'une composition pharmaceutique pour le traitement de la rosacee | |
EP1686978B1 (fr) | Utilisation de l'idrocilamide pour la preparation d'une composition pharmaceutique pour le traitement de la rosacee | |
EP1718296A2 (fr) | Utilisation du metronidazole pour le traitement des pathologies liees au recepteur de type b de l'interleukine 8 et/ou au recepteur de type 1 de pacap | |
EP1718285A2 (fr) | Utilisation d'un compose modulateur d'au moins un recepteur choisi parmi le recepteur de type b de l'il 8 et de type 1 de pacap pour la preparation d'une composition pharmaceutique pour traiter la rosacee | |
WO2014049295A1 (fr) | Combinaison de laropiprant et de doxycycline pour le traitement de la rosacée | |
FR2899475A1 (fr) | Composition pharmaceutique pour le traitement de la rosacee | |
EP1732542A2 (fr) | Utilisation du metronidazole pour le traitement d'un desordre de la vascularisaton cutanee | |
FR2862539A1 (fr) | Utilisation du piketoprofen pour la fabrication d'une composition pharmaceutique pour le traitement de la rosacee | |
WO2005079786A1 (fr) | Utilisation d’un compose modifiant la secretion de l’interleukine 5, de l’interleukine 6 et/ou de l’interleukine 10 pour la preparation d’une composition pharmaceutique destinee a traiter la rosacee | |
WO2005089751A2 (fr) | Utilisation du metronidazole pour le traitement d’une inflammation cutanee |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005802503 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2578121 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007531796 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11723378 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005802503 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11723378 Country of ref document: US |